However, there were mostly non-statistically significant risks across all five clinical outcomes associated with new users of SGLT-2 inhibitors compared with new users of DPP-4 inhibitors and GLP-1 agonists and users of older agents; the only exception was that new users of SGLT-2 inhibitors were more likely to have higher rates of peripheral vascular diseases compared with new users of GLP-1 agonists (aHR, 1.47; 95% CIs, 1.03–2.09). This evidence concerns the gene SLC5A2 and vascular disorder.